Polycyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/100)
  • Publication number: 20110082098
    Abstract: Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.
    Type: Application
    Filed: September 30, 2010
    Publication date: April 7, 2011
    Applicant: UNIVERSITY OF KANSAS
    Inventors: James P. Calvet, Brian S.J. Blagg, Shirin V. Sundar, Brenda S. Magenheimer
  • Publication number: 20110082076
    Abstract: Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compositions of the present invention have superior stability to other microparticle compositions resulting in a microparticle composition with longer shelf life and improved dispersability. The microparticle compositions of the present invention have a transition temperature (Tg) of at least 20° C. above the recommended storage temperature (Tst) for drug delivery.
    Type: Application
    Filed: December 14, 2010
    Publication date: April 7, 2011
    Applicant: NOVARTIS AG
    Inventors: Luis A. Dellamary, Jean Riess, Ernest G. Schutt, Jeffry G. Weers, Thomas E. Tarara
  • Publication number: 20110065631
    Abstract: A process for the synthesis of bisfuran intermediates of formula (0) useful for preparing antiviral HIV protease inhibitor compounds is hereby disclosed. Furthermore disclosed is a HIV protease inhibitor of formula (IV) as well as various intermediates thereof.
    Type: Application
    Filed: March 29, 2007
    Publication date: March 17, 2011
    Applicant: Gilead Sciences, Inc
    Inventors: Kenneth R. Crawford, Eric D. Dowdy, Arnold Gutierrez, Richard Polniaszek, Richard H. Yu
  • Patent number: 7902228
    Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.
    Type: Grant
    Filed: February 4, 2008
    Date of Patent: March 8, 2011
    Assignees: University of Iowa Research Foundation, The United States of America, National Institute of Health
    Inventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
  • Publication number: 20110053847
    Abstract: The invention encompasses methods of decreasing the lumenal diameter of a blood vessel by contacting the vessel with a myosin light chain phosphatase inhibitor.
    Type: Application
    Filed: November 9, 2010
    Publication date: March 3, 2011
    Applicant: THE WASHINGTON UNIVERSITY
    Inventor: Walter A. Boyle
  • Publication number: 20110038952
    Abstract: This invention relates with the gambogic acid glycoside derivatives and analogs of formula I: or stereoisomers, tautoers, prodrugs, pharmaceutically acceptable salts, complex salts or solvates thereof, wherein: X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 or/and R12 is, independently at each occurrence, optionally substituted glycosyl, optionally substituted multi-hydroxyl, optional substituent oxy, optional substituent containing carbon, oxygen, sulfur, nitrogen or phosphorus element. Compounds of the present invention are useful as therapeutically effective agents of anti-cancer, anti-virus and anti-bacterial. This invention also relates with their preparative methods and applications.
    Type: Application
    Filed: September 26, 2008
    Publication date: February 17, 2011
    Inventor: Lifeng Xu
  • Publication number: 20110028437
    Abstract: The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide lowered side effects when phosphorylated pyrone analogs are coadministered with therapeutic agents.
    Type: Application
    Filed: August 13, 2010
    Publication date: February 3, 2011
    Applicant: Limerick BioPharma, Inc.
    Inventors: Wendye Robbins, Ving Lee
  • Publication number: 20110003774
    Abstract: There is provided a method of inhibiting the occurrence of one of more of the following conditions:—the proliferation of monocytes/macrophages; or—the proliferation of smooth muscle cells; or—the expression of CD36 receptors; or—the uptake of oxidized LDL, the method comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents.
    Type: Application
    Filed: July 12, 2010
    Publication date: January 6, 2011
    Applicant: VITAL HEALTH SCIENCES PTY. LTD.
    Inventors: Simon Michael West, Esra Ogru
  • Publication number: 20100317625
    Abstract: This invention provides novel ?-lactamase inhibitors of the aryl- and heteroaryl-sulfonamidomethylphosphonate monoester class. The compounds inhibit three classes of ?-lactamases and synergize the antibacterial effects of ?-lactam antibiotics (e.g., imipenem and ceftazimdime) against those micro-organisms normally resistant to the ?-lactam antibiotics as a result of the presence of the ?-lactamases.
    Type: Application
    Filed: May 21, 2007
    Publication date: December 16, 2010
    Inventors: Frank Dininno, Milton L. Hammond, Kevin Dykstra, Seongkon Kim, Qiang Tan, Katherine Young, Jeffrey Donald Hermes, Stephane Raeppel, Michael Mannion, Nancy Z. Zhou, Frederic Gaudette, Arkadii Vaisburg, Jubrail Rahil, Nafsika Georgopapadakou
  • Publication number: 20100305070
    Abstract: The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer.
    Type: Application
    Filed: April 30, 2010
    Publication date: December 2, 2010
    Applicant: The University Court of the University of Dundee
    Inventors: Steven Albert Everett, Saraj Ulhaq
  • Publication number: 20100297020
    Abstract: Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof. Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents. Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment. Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof.
    Type: Application
    Filed: April 9, 2010
    Publication date: November 25, 2010
    Applicant: Limerick Biopharma, Inc.
    Inventors: May Dean-Ming Lee, Ving Lee, Wendye Robbins
  • Publication number: 20100298272
    Abstract: A new anticancer compounds of formula (1) Drugs and pharmaceutical compositions to be used in human or veterinary medicine, which include at least one compound of formula (1).
    Type: Application
    Filed: July 7, 2008
    Publication date: November 25, 2010
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jean-Luc Pirat, David Virieux, Ludovic Clarion, Jean-Noel Volle, Norbert Bakalara, Marcel Mersel, Jerome Montbrun, Henri-Jean Cristau
  • Publication number: 20100292190
    Abstract: The present invention relates to compounds of general formula (I) as tublin polymerisation inhibitors and methods for preparing such compounds.
    Type: Application
    Filed: February 14, 2006
    Publication date: November 18, 2010
    Applicant: Bionomics Limited
    Inventors: Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Bernard Luke Flynn
  • Publication number: 20100279983
    Abstract: This invention provides novel ?-lactamase inhibitors of the aryl- and heteroarylsulfonamidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammonium groups. The compounds inhibit three classes of ?-lactamases and synergize the antibacterial effects of ?-lactam antibiotics (e.g., imipenem and ceftazidime) against those micro-organisms normally resistant to the ?-lactam antibiotics as a result of the presence of the ?-lactamases. Formula (I) or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 21, 2007
    Publication date: November 4, 2010
    Inventors: Frank Dininno, Milton L. Hammond, Kevin Dykstra, Seongkon Kim, Qiang Tan, Katherine Young, Jeffrey Donald Hermes, Helen Chen, Stephane Raeppel, Michael Mannion, Frederic Gaudette, Arkadii Vaisburg, Jubrail Rahil, Nafsika Georgopapadakou, Nancy Z. Zhou
  • Publication number: 20100267673
    Abstract: Tocopheryl succinate derivatives according to formula I: are described. These compounds increase the activity of protein phosphatase 2A, can be included in pharmaceutical compositions, and can be used for the treatment of androgen receptor-dependent cancers such as prostate cancer.
    Type: Application
    Filed: April 13, 2010
    Publication date: October 21, 2010
    Applicant: THE OHIO SATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Publication number: 20100209459
    Abstract: There is provided an alkaloid formulation comprising the reaction product of one or more alkaloids with one or more phosphate derivatives of one or more electron transfer agents.
    Type: Application
    Filed: January 20, 2010
    Publication date: August 19, 2010
    Inventors: Simon Michael WEST, Esra OGRU, Robert GIANELLO
  • Publication number: 20100204183
    Abstract: The invention relates to novel and known substituted phosphonates for use in ameliorating amyloid aggregates, particularly for use in the treatment of Alzheimer's disease.
    Type: Application
    Filed: May 2, 2008
    Publication date: August 12, 2010
    Applicant: QUEEN MARY & WESTFIELD COLLEGE
    Inventors: Alice Sullivan, Adina Michael-Titus, Lesley Robson
  • Publication number: 20100204089
    Abstract: The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide lowered side effects when phosphorylated pyrone analogs are coadministered with therapeutic agents.
    Type: Application
    Filed: April 22, 2010
    Publication date: August 12, 2010
    Inventors: Wendye Robbins, Ving Lee
  • Publication number: 20100189653
    Abstract: Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof. Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents. Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment. Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof.
    Type: Application
    Filed: October 9, 2009
    Publication date: July 29, 2010
    Inventors: Wendye Robbins, Ving Lee, May Dean-Ming Lee
  • Publication number: 20100183517
    Abstract: Compounds of the formula, A-L-B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific membrane antigen (PMSA). Such compounds are useful in treatment of prostate cancer; and when chemically attached to a fluorescent dye, can efficiently and selectively label prostate cancer cells for fluorescent imaging.
    Type: Application
    Filed: January 22, 2010
    Publication date: July 22, 2010
    Applicant: CANCER TARGETED TECHNOLOGY LLC
    Inventor: Cliff Berkman
  • Publication number: 20100173014
    Abstract: The instant invention discloses methods of preparing phospholipid delivery systems encapsulating one or more bio-affecting compounds, said methods comprising solubilizing a heterogeneous phospholipid mixture into a suitable organic solvent to form a concentrated formulation of phospholipids, wherein the phospholipids comprise a charged phospholipid species, and mixing the concentrated formulation with an aqueous solution comprising at least one bio-affecting compound. The instant invention also discloses methods of using a phospholipid delivery system encapsulating at least one bio-affecting compound for administration to an individual in need thereof.
    Type: Application
    Filed: May 24, 2007
    Publication date: July 8, 2010
    Applicant: Nanosolutions, LLC
    Inventor: Michael W. Fountain
  • Publication number: 20100144612
    Abstract: The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide lowered side effects when phosphorylated pyrone analogs are coadministered with therapeutic agents.
    Type: Application
    Filed: February 18, 2010
    Publication date: June 10, 2010
    Inventors: Wendye ROBBINS, Ving Lee
  • Publication number: 20100143296
    Abstract: The present invention relates to new podophyllotoxin inhibitors of topoisomerase II, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: December 10, 2009
    Publication date: June 10, 2010
    Applicant: AUSPEX PHARMACEUTICALS, INC.
    Inventor: Thomas G. Gant
  • Publication number: 20100130448
    Abstract: The present invention provides a 3?,4?,5-trimethoxy flavone derivative and a pharmaceutically acceptable salt thereof, preparation thereof, and a pharmaceutical composition for the treatment and prevention of dry eye syndrome comprising the same as an active ingredient. The 3?,4?,5-trimethoxy flavone derivative and its pharmaceutically acceptable salt inhibit corneal damage through excellent stimulatory action on mucus secretion in the conjunctiva and therefore may be effective as a prophylactic or therapeutic agent for dry eye syndrome.
    Type: Application
    Filed: June 2, 2008
    Publication date: May 27, 2010
    Applicant: DONG-A PHARM. CO., LTD
    Inventors: Seul-Min Choi, Kyung-Koo Kang, Dong-Sung Kim, Jeong-Hoon Kim, Byoung-Ok Ahn, Moo-Hi Yoo, Mi-Jeong Seo, Ju-Mi Kim, Yong-Duck Kim, Sun-Woo Jang, Yong-Sung Shon
  • Patent number: 7718633
    Abstract: A compound of the formula is disclosed as a prodrug of an HIV protease inhibitor. Methods and compositions for inhibiting HIV protease activity and treating HIV infection are also disclosed.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: May 18, 2010
    Assignee: Abbott Laboratories
    Inventors: David A. DeGoey, William J. Flosi, David J. Grampovnik, Larry L. Klein, Dale J. Kempf, Xiu C. Wang
  • Publication number: 20100048512
    Abstract: Administration of either a tocopherol represented by the general formula (1) or a tocotrienol compound ester derivative before or after exposure to radiation is effective in preventing or treating health disorders caused by the radiation exposure.
    Type: Application
    Filed: November 14, 2007
    Publication date: February 25, 2010
    Applicants: National Institute of Radiological Sciences, Fukuoka University
    Inventors: Kazunori Anzai, Megumi Ueno, Haruko Yakumaru, Junichi Ueda, Makoto Akashi, Shizuko Kobayashi, Jiro Takata, Nobuo Ikota
  • Publication number: 20100016261
    Abstract: A compound of formula (I) is described; wherein the substituents are as defined in the text and wherein the compound is intended for use in the production of a vascular damaging effect in a warm-blooded animal.
    Type: Application
    Filed: December 19, 2007
    Publication date: January 21, 2010
    Inventors: Timothy William Wallace, David John Edwards, John Anthony Hadfield
  • Publication number: 20100004208
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.
    Type: Application
    Filed: February 2, 2007
    Publication date: January 7, 2010
    Applicant: BIONOMICS LIMITED
    Inventors: Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
  • Publication number: 20100004209
    Abstract: The present invention relates to compounds of the formula (I), where R1 to each, independently of one another, denote H, hydroxyl or alkoxy having 1 to 8 C atoms, R4 denotes alkyl having 1 to 4 C atoms, H, hydroxyl or alkoxy having 1 to 8 C atoms, R5 denotes H or hydroxyl, and R6 denotes H or alkyl having 1 to 18 C atoms, or salts thereof, but where all R1 to R4 together cannot be equal to H, to compositions, and to the preparation and use thereof.
    Type: Application
    Filed: October 4, 2007
    Publication date: January 7, 2010
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: Christophe Carola, Herwig Buchholz
  • Publication number: 20090325906
    Abstract: Methods and compositions are described for the modulation of hyperglycemia and/or one or more symptoms of hyperglycemia. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of calcineurin inhibitors out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity to increase the efflux of calcineurin inhibitor from physiological compartments.
    Type: Application
    Filed: June 26, 2009
    Publication date: December 31, 2009
    Inventors: Wendye Robbins, Ving Lee
  • Publication number: 20090291923
    Abstract: The invention provides novel trioxane dimers having formulae III, IV or V: methods for their preparation, pharmaceutical compositions containing these compounds, and methods for treating cancer and/or malaria using these compounds and compositions.
    Type: Application
    Filed: November 17, 2006
    Publication date: November 26, 2009
    Applicants: Johns Hopkins Universoty, The Government of the United States of America as Represented by the Secretary of the DHHS NIH, Offi
    Inventors: Gary H. Posner, Ikhyeon Paik, Kristina Borstnik, Wonsuk Chang, Sandra Sinishtaj, William Malo, John Gaetano D'Angelo, Lauren Elaine Woodard, Alvin Solomon Kalinda, Aimee R. Usera, Lindsey Catherine Hess, Andrew Scott Rosenthal, Seongho Oh, Astrid C. Baege
  • Publication number: 20090285884
    Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.
    Type: Application
    Filed: July 21, 2009
    Publication date: November 19, 2009
    Applicant: University of South Florida
    Inventors: Heidi Kay, Jay W. Palmer, Joseph A. Stanko
  • Patent number: 7612051
    Abstract: This invention relates to a powder composition comprising a silicone represented by the following formula (1) comprising an alcoholic hydroxyl group, and a powder, to an oil-based powder composition formed by dispersing this powder composition in an oil, and to a cosmetic material containing these materials. R1aR2bR3cSiO(4?a?b?c)/2??(1) where, in formula (1), R1 are identical or different organic groups selected from alkyl groups, aryl, aralkyl or fluorinated alkyl groups having 1-30 carbon atoms, R2 is a substituent having one or more alcoholic hydroxy groups, R3 is a group represented by the following general formula (2), ?and a, b, c, d are integers satisfying the relations: 1.0?a?2.5, 0.01?b?1, 0.001?c?1, 1.5?a+b+c?2.6, and 0?d?500. The powder composition of this invention has little cohesion, excellent dispersibility and excellent stability over time as an oil-based powder composition.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: November 3, 2009
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Masanao Kamei, Toru Shimizu
  • Publication number: 20090239827
    Abstract: There is provided a therapy for lowering the blood levels of a lipid selected from the group comprising LDL cholesterol, triglycerides, overall cholesterol and mixtures thereof, the therapy comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents.
    Type: Application
    Filed: January 6, 2006
    Publication date: September 24, 2009
    Inventors: Esra Ogru, Roksan Libinaki, Simon Michael West
  • Publication number: 20090233884
    Abstract: The invention relates to the use of a compound of the formula (I) for the treatment of bacterial infections caused by mycobacteria and related microorganisms, such as tuberculosis, leprosy, nocardiosis, diphtheria, pulmonary mycobacterial infection, cutaneous mycobacterial infection, atypical mycobacterial infection and mycobacteriosis.
    Type: Application
    Filed: February 6, 2009
    Publication date: September 17, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard SEIBERT, Luigi TOTI, Joachim WINK
  • Publication number: 20090227543
    Abstract: The invention is related to phosphonate substituted compounds having immuno-modulatory activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: July 1, 2008
    Publication date: September 10, 2009
    Inventors: Carina Cannizzaro, James M. Chen, Xiaowu Chen, Aesop Cho, Lee S. Chong, Manoj Desai, Maria Fardis, Alan X. Huang, Thorsten Kirschberg, Christopher P. Lee, Richard L. Mackman, Peter H. Nelson, Hyung-Jung Pyun, Adrian S. Ray, William J. Watkins, Jennifer R. Zhang, Sundaramoorthi Swaminathan
  • Publication number: 20090203649
    Abstract: A dermatological anti-wrinkle agent and an anti-wrinkle cosmetic are stable and satisfactorily effective against wrinkles. The dermatological anti-wrinkle agent comprises a tocopherol phosphate represented by the following formula (1): and/or a salt thereof, wherein R1, R2, and R3 represent a hydrogen atom or a methyl group. The anti-wrinkle cosmetic includes the anti-wrinkle agent.
    Type: Application
    Filed: June 25, 2007
    Publication date: August 13, 2009
    Applicant: SHOWA DENKO K.K.
    Inventors: Eiko Kato, Toshi Tsuzuki
  • Patent number: 7569558
    Abstract: The present invention relates to a method for topical delivery of trace metals for the modulation of certain metalloenzymes. The method of topical delivery of the present invention comprises; (i) mixing of a trace metal salt of a phosphorylated nitrogen heterocyclic base complexed with a chelating agent [Figure l], and (ii) a carrier, and (iii) topical application of said mixture. The modulation of metalloenzymes such as Superoxide Dismutase, Elastase, Tyrosinase, Matrix metalloproteases, and Ubiquitin-Proteasome pathway by the methods of the present invention is useful for providing anti-inflammatory, skin whitening, wrinkles reduction, skin aging control, cellular antioxidant, acne control, hair growth modulation, and skin damage control benefits.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: August 4, 2009
    Assignee: Bioderm Research
    Inventor: Shyam K Gupta
  • Publication number: 20090186856
    Abstract: There is provided a dietary or health supplement comprising an effective amount of a micronutrient selected from the group consisting of phosphate derivatives of tocopherol, ubiquinol, ascorbic acid, tocotrienol, retinol and mixtures thereof delivered with an acceptable carrier.
    Type: Application
    Filed: September 18, 2008
    Publication date: July 23, 2009
    Applicant: VITAL HEALTH SCIENCES PTY. LTD.
    Inventors: Simon Michael West, David Kannar
  • Publication number: 20090170814
    Abstract: 7,8-Bicyclic-chroman derivatives of Formula I: wherein the substituents are defined as in the specification or the pharmaceutically acceptable salts thereof, are disclosed. They are useful for the treatment of inflammatory disorders, neurodegenerative disorders and/or mitochondrial disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.
    Type: Application
    Filed: November 24, 2008
    Publication date: July 2, 2009
    Applicant: Edison Pharmaceuticals, inc.
    Inventors: Bing Wang, Gail Walkinshaw
  • Publication number: 20090104258
    Abstract: The invention relates to a cosmetic composition of a tocopheryl phosphate, especially in its dl or d form, or in the form of a cosmetically acceptable salt or ester thereof, as a cosmetic agent for preventing or slowing down the appearance of the effects of skin ageing, in particular of photoageing of the skin, said tocopheryl phosphate being at least partially encapsulated in lipid vesicles, in particular liposomes. It relates most particularly to the use of alpha-tocopheryl phosphate. It also relates to cosmetic compositions containing a tocopheryl phosphate, in particular an alpha-tocopheryl phosphate, at least partially incorporated into lipid vesicles, in particular liposomes, these compositions being in particular in the form of a serum or of a stable emulsion. The invention also relates to a cosmetic skincare process.
    Type: Application
    Filed: September 25, 2008
    Publication date: April 23, 2009
    Applicant: LVMH RECHERCHE
    Inventors: Marc Dumas, Emmanuelle Noblesse, Valerie Alard, Dominique Quiles, Eric Perrier
  • Patent number: 7514244
    Abstract: A process for preparing lipids which contain docosahexaenoic acid (DHA) and/or docosapentaenoic acid (DPA) is disclosed. The process includes the steps of cultivating in a medium a microorganism which belongs to the genus Ulkenia having the ability to produce DHA and/or DPA and recovering the lipids from the culture. The process may further include the step of separating DHA and/or DPA from the lipids.
    Type: Grant
    Filed: January 13, 2003
    Date of Patent: April 7, 2009
    Assignees: Suntory Ltd., Nagase & Co., Ltd., Nagase Chemtex Corporation
    Inventors: Satohiro Tanaka, Toshiaki Yaguchi, Sakayu Shimizu, Tsutomu Sogo, Shigeaki Fujikawa
  • Publication number: 20090082313
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 25, 2008
    Publication date: March 26, 2009
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Sergei Agoulnik, Bruce Decosta, Hong Du, Yimin Jiang, Xiang-Yi Li, Kenichi Nomoto, John (Yuan) Wang, Huiming Zhang
  • Publication number: 20090069273
    Abstract: The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide lowered side effects when phosphorylated pyrone analogs are coadministered with therapeutic agents.
    Type: Application
    Filed: July 30, 2008
    Publication date: March 12, 2009
    Inventors: Wendye ROBBINS, Ving Lee
  • Publication number: 20090054376
    Abstract: The present invention relates to novel benzofuran compounds, to pharmaceutical compositions that include such compounds, and to methods of use thereof. Certain compounds of the invention share some pharmacological properties with cannabinoids and have a common wide range of beneficial therapeutic indications. In particular, compounds of the invention are useful as analgesic, neuroprotective, immunomodulatory and anti-inflammatory agents.
    Type: Application
    Filed: May 31, 2006
    Publication date: February 26, 2009
    Inventors: Avihai Yacovan, Flavio Grynszpan, Alexander Aizikovich, Marcus Stephen Brody, Avi Bar-Joseph, Sigal Meilin
  • Publication number: 20090036409
    Abstract: The present invention is directed to a compound of formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof, and methods for treating inflammatory and serine protease mediated disorders.
    Type: Application
    Filed: August 20, 2008
    Publication date: February 5, 2009
    Inventors: Michael J. Hawkins, Michael N. Greco, Eugene Powell, Lawrence De Garavilla, Bruce E. Maryanoff
  • Publication number: 20090028925
    Abstract: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.
    Type: Application
    Filed: May 26, 2006
    Publication date: January 29, 2009
    Inventors: Mark D. Erion, Hongjian Jiang, Serge H. Boyer
  • Publication number: 20090005348
    Abstract: A method of modulating one or more immuno-regulatory cytokines, such as pro-inflammatory and/or anti-inflammatory cytokines, comprising administering to a subject a therapeutically effective amount of one or more phosphate derivatives of one or more hydroxy chromans, or complexes thereof.
    Type: Application
    Filed: December 22, 2006
    Publication date: January 1, 2009
    Applicant: VITAL HEALTH SCIENCES PTY LTD
    Inventors: Esra Ogru, Roksan Libinaki, Robert Gianello
  • Patent number: 7456214
    Abstract: Chrome compounds have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: November 25, 2008
    Assignees: Baylor University, OXiGENE, Inc.
    Inventors: Kevin G. Pinney, Phyllis Arthasary, Anupama Shirali, Klaus Edvardsen, David J. Chaplin
  • Publication number: 20080275005
    Abstract: The invention provides mitochondrially targeted antioxidant compounds. A compound of the invention comprises a lipophilic cation covalently coupled to an antioxidant moiety. In preferred embodiments, the lipophilic cation is the triphenyl phosphonium cation, and the compound is of the formula P(Ph3)+XR.Z- where X is a linking group, Z is an anion and R is an antioxidant moiety. Also provided are pharmaceutical compositions containing the mitochondrially targeted antioxidant compounds, and methods of therapy or prophylaxis of patients who would benefit from reduced oxidative stress, which comprise the step of administering the compounds of the invention.
    Type: Application
    Filed: April 24, 2008
    Publication date: November 6, 2008
    Inventors: Michael P. Murphy, Robin A.J. Smith